

1 **Translation is required for miRNA-dependent decay of endogenous**
2 **transcripts.**

3

4 Adriano Biasini¹, Stefano de Pretis², Jennifer Y. Tan¹, Baroj Abdulkarim¹, Harry
5 Wischniewski³, Rene Dreos⁴, Mattia Pelizzola², Constance Ciaudo³ and Ana Claudia
6 Marques^{1*}

7

8 ¹Department of Computational Biology, University of Lausanne, Switzerland

9 ²Center for Genomic Sciences, Istituto Italiano di Tecnologia (IIT), Milano, Italy

10 ³Institute of Molecular Health Sciences, ETHZ, Zurich, Switzerland

11 ⁴Center for Integrative Genomics, University of Lausanne, Switzerland

12 * Corresponding Author (anaclaudia.marques@unil.ch)

13

14 Posttranscriptional repression by microRNA (miRNA) occurs through transcript
15 destabilization or translation inhibition. Whereas RNA degradation explains most
16 miRNA-dependent repression, transcript decay occurs co-translationally, raising
17 questions regarding the requirement of target translation to miRNA-dependent
18 transcript destabilization. To assess the contribution of translation to miRNA-mediated
19 RNA destabilization, we decoupled these two molecular processes by dissecting the
20 impact of miRNA loss of function on cytosolic long noncoding RNAs (lncRNAs). We
21 show, that despite interacting with miRNA loaded RNA-induced silencing complex
22 (miRISC), the steady state abundance and degradation rates of these endogenously
23 expressed non-translated transcripts are minimally impacted by miRNA loss. To
24 validate the requirement of translation for miRNA-dependent decay, we fused a
25 miRISC bound lncRNA, whose levels are unaffected by miRNAs, to the 3'end of a
26 protein-coding gene reporter and show that this results in its miRNA-dependent
27 transcript destabilization. Furthermore, analysis of the few lncRNAs whose levels are
28 regulated by miRNAs revealed these tend to associate with translating ribosomes and
29 are likely misannotated micropeptides, further substantiating the necessity of target
30 translation for miRNA-dependent transcript decay. Our analyses reveal the strict
31 requirement of translation for miRNA-dependent transcript destabilization and
32 demonstrate that the levels of coding and noncoding transcripts are differently affected
33 by miRNAs.

1 INTRODUCTION

2

3 Post-transcriptional regulation of gene expression by microRNAs (miRNAs) is
4 widespread in eukaryotes and impacts diverse biological processes in health and
5 disease [1, 2]. Most mature miRNAs are the product of a relatively complex biogenesis
6 process. Primary miRNA transcripts, that generally depend on RNA Polymerase II for
7 transcription, are initially processed by the nuclear enzyme DROSHA and its cofactor
8 DGCR8 into a premature hairpin RNA of ~60 nucleotides in length (pre-miRNA
9 transcript) [3]. Pre-miRNAs are exported into the cytoplasm where they undergo a
10 second round of processing by DICER resulting in a ~22 nucleotide long double-
11 stranded RNA duplex [4]. Loss of function mutations in any of the miRNA processing
12 factors result in complete depletion of most miRNA species [5]. Argonaute proteins
13 (AGO) bind mature miRNAs and guide target recognition of the RNA-inducing
14 silencing complex (RISC). In mammals, target recognition relies primarily on
15 complementarity between the miRNA seed region (position 2-8 of the mature miRNA)
16 and miRNA recognition elements (MREs) in the target [6].

17 Posttranscriptional repression by miRNAs occurs by translation inhibition or transcript
18 decay [2]. The contributions of RNA destabilization and translation inhibition to miRNA
19 repression have been extensively studied [7, 8]. These studies support the general
20 consensus that, translation inhibition precedes transcript deadenylation and decay [9-
21 11], which in turn, is thought to account for most miRNA-dependent repression [9, 10,
22 12]. The coupling between translation inhibition and transcript destabilisation is further
23 substantiated by evidence that protein-coding transcripts undergoing miRNA-
24 dependent repression associate with translating ribosomes [13-19], and that most
25 miRNAs loaded into RISC (miRISC) co-localize with polysomes [20-22].

26 These observations have raised questions regarding the requirement of translation for
27 miRNA-dependent transcript decay. A number of experiments relying on the analysis
28 of reporter constructs, revealed that transcript decay occurs even when translation
29 initiation or elongation are impaired [23-25]. However, it is hard to reconcile the extent
30 of target repression reported in these studies (up to five-fold) with the well-established
31 impact of most miRNAs on endogenous transcript abundance, which rarely exceeds
32 2-fold [9, 10]. This has prompted concerns on whether exogenously expressed
33 reporters faithfully recall the behaviour of most endogenously expressed transcripts.

1 To assess the requirement of translation for RNA destabilization of endogenous
2 miRNA-targets and to overcome some of the limitations that may arise from using
3 exogenous reporters, we took advantage of endogenously expressed cytosolic
4 intergenic long noncoding RNAs, lncRNAs. This class of noncoding transcripts rarely
5 associate with ribosomes [26] and have been previously shown to interact with miRISC
6 machinery [27]. These transcripts thus provide a unique opportunity to address the
7 outstanding question of whether miRNA-dependent decay occurs in the absence of
8 translation. Specifically, we used 4-thio-uridine (4sU) to assess genome wide decay
9 rates in wild-type (WT) and miRNA depleted cells. Our genome-wide analysis revealed
10 that the decay rates of protein coding miRNA targets are significantly reduced upon
11 miRNA loss whereas those of lncRNAs are only minimally impacted. Putative
12 micropeptides were enriched among lncRNAs responsive to changes in miRNA
13 abundance suggesting that translation is required for miRNA-dependent decay. We
14 validated this hypothesis experimentally by inducing association of candidate lncRNA
15 with translating ribosomes and found that this is sufficient to induce miRNA-dependent
16 decay, further substantiating the prerequisite of translation for miRNA-dependent
17 transcript decay.
18

1 RESULTS

2

3 Cytosolic lncRNAs interact with miRISC

4 Since posttranscriptional regulation by miRNAs occurs in the cytoplasm [6] and does
5 not directly impact the levels of nuclear lncRNAs, we first classified lncRNAs based on
6 their subcellular localization. We used RNA sequencing data from mESCs' nuclear
7 and cytosolic fractions [28] to estimate the expression of protein-coding transcripts
8 (mRNAs) and intergenic long noncoding RNAs (lncRNAs) in these two subcellular
9 compartments (Supplementary Figure S1A). We considered lncRNAs with a
10 cytoplasmic/nuclear expression ratio higher than the median ratio for mRNA, which
11 are predominantly located in the cytoplasm, to be cytosolic (n=1081). The remaining
12 mESC lncRNAs, were considered to be nuclear (n=4953). Ribosome profiling data in
13 mESCs [29] supports that mRNAs (50.4%) are more frequently associated with
14 translating ribosomes than cytosolic or nuclear lncRNAs (6.6% and 4.0%, respectively,
15 two-tailed Chi-square test, p -value $< 10^{-4}$, Figure 1A). We took advantage of publicly
16 available AGO2-CLIP [30] data for wild-type and DICER knockout mESCs, to assess
17 whether cytosolic lncRNAs are associated with miRISC. We found that the fraction of
18 mESC expressed cytosolic lncRNAs and mRNAs with experimental evidence for
19 AGO2 binding is similar, (6% and 7% respectively, two-tailed Chi-square test, p -
20 value=0.16), as is the density of bound sites within cytosolic lncRNAs (1.0 sites per kb
21 of sequence) and mRNA 3'UTRs (0.7 sites per kb of sequence, two-tailed Mann-
22 Whitney test, p -value <0.05 , Figure 1B). Our ability to detect binding by miRISC, using
23 this approach, is in part limited by the endogenous expression of transcripts as
24 highlighted by the significantly higher expression of transcripts bound by AGO2
25 (average expression (TPM) bound=9.0 vs unbound=5.4, two-tailed Mann-Whitney
26 test, $p<2\times 10^{-26}$ Supplementary Figure S1B). Since lncRNAs are in general more lowly
27 expressed than mRNAs, the proportion of lncRNAs bound by AGO2 may be higher
28 than what is detected. The fraction of cytosolic lncRNAs bound by AGO2 with (6%)
29 and without (7%) experimental evidence of ribosomal association is statistically
30 indistinguishable (two-tailed Fisher's exact test $p=0.8$), suggesting that AGO2 binding
31 is independent of translation. We conclude, that consistent with previous analysis,
32 most cytosolic lncRNAs do not stably associate with translating ribosomes [26], but
33 are nevertheless targeted by miRISC [27], and are therefore, uniquely suitable to

1 assess the impact of miRNAs on endogenous transcript destabilization in absence of
2 translation.

3

4 **Steady-state expression of noncoding transcripts is minimally impacted by** 5 **miRNAs**

6 We first sought to determine whether cytosolic lncRNA expression was post-
7 transcriptionally regulated by miRNAs. We took advantage of a mESC cell line
8 containing two Cre/LoxP sites flanking the *Dicer* RNase III domain on exon 21, and a
9 Cre recombinase gene expressed under the control of a 4-hydroxytamoxifen(4-OHT)-
10 inducible promoter [31, 32]. Exposure of these cells to 4-OHT leads to LoxP site
11 recombination and strong depletion of DICER (Supplementary Figure S1C).
12 Conditional loss of DICER function minimally impacts cell proliferation (Supplementary
13 Figure S1D) and the transcript and protein levels of (Supplementary Figure S1E-G) of
14 the pluripotency transcription factors, Nanog, Oct4 and Sox2. In contrast to what was
15 previously reported for *Dicer* constitutive knockdown mESCs, that exhibit an 10-fold
16 downregulation of *c-Myc* expression [33], in conditional *Dicer* mESC mutants the
17 expression of this gene is only minimally impacted (Fold-change between KO and WT
18 > 0.5, Supplementary Figure S1E), supporting that this system is better suited to
19 investigate the direct effects of miRNA depletion.

20 We profiled small RNA expression following DICER loss of function and found that 8
21 days after 4-OHT addition, mature miRNA levels are reduced by ~80% (Figure 1C).
22 We validated these results, by RT-qPCR, for miR-290 and miR-295, which are among
23 the most abundant miRNAs in mESCs [34] (Supplementary Figure S1H). Decreased
24 levels of these miRNAs is associated, as expected, with a significant increase in the
25 levels of some of their well-established targets [35] (Supplementary Figure S1I).

26 To assess the genome-wide impact of miRNA loss on mRNA and lncRNA expression,
27 we used data from our previously published transcriptome-wide expression profiling
28 following loss of DICER experiment in these cells [28]. As expected, and consistent
29 with the role of miRNAs on posttranscriptional repression of protein-coding gene
30 expression, we found that mRNA levels increased moderately but significantly
31 following *Dicer* loss of function (Figure 1D). The fold-increase in expression, relative
32 to control, in miRNA depleted mESCs is significantly higher (two-tailed Mann-Whitney
33 test, $p < 1.4 \times 10^{-10}$) for transcripts with experimental evidence for AGO2 binding (Figure
34 1E), supporting that the observed changes in mRNA expression are, at least in part,

1 a consequence of mRNA alleviation from miRNA-mediated repression. In contrast to
2 mRNAs, we found that lncRNA expression was minimally impacted by miRNA
3 depletion (Figure 1F). Specifically, and in contrast to mRNAs, lncRNA steady-state
4 abundance is slightly decreased in miRNA depleted cells (Figure 1F). This small
5 decrease is likely an indirect effect of miRNA loss. Specifically, decreased levels of
6 miRNAs are expected to result in increased steady state abundance of targets as
7 observed for mRNAs (Figure 1F), whereas the impact of miRNA depletion is similar
8 for both subcellular classes of lncRNA independent of co-localization with miRISC
9 (Figure 1F). We conclude that, despite interacting with miRISC, cytosolic lncRNA
10 transcript levels are not directly controlled by miRNAs (Figure 1F).

11

12 **No evidence for miRNA-dependent destabilization of noncoding transcripts**

13 Steady-state transcript abundance depends on the rates of transcription, processing
14 and degradation but only the degradation is directly controlled by miRNAs. To
15 determine transcriptome-wide differences in degradation rate between miRNA
16 depleted and control mESCs we performed, in duplicate, 4-thio-uridine (4sU, 200uM)
17 metabolic labelling of RNA for 10 and 15 minutes, on mESCs 8 days after induction of
18 DICER loss of function and control mESC. We sequenced total RNA and quantified
19 intron and exon expression transcriptome wide from the pre-existing and newly
20 synthesized RNA fractions. (Figure 2A, Methods). Principal component analysis of the
21 gene expression estimates across the different samples revealed that the RNA
22 fraction is the strongest discriminator between estimates followed by miRNA content
23 and lastly by biological replicate (Supplementary Figures S2A-C). Degradation rates,
24 that we estimated using INSPEcT ([36], methods) for the two different pulse durations
25 (10 and 15 minutes) are highly correlated for both cell types ($R^2 > 0.75$, Figure 2B-C).
26 We used an alternative method (transcription block by Actinomycin-D) to validate the
27 estimated differences in transcript stability between wild-type and miRNA depleted
28 cells for a subset of transcripts spanning a range of fold-differences in degradation
29 rates (Pearson $R^2 = 0.58$, Supplementary Figure 2D).

30 Next, we identified genes whose degradation rate is significantly different between
31 miRNA-depleted and control mESCs (10 and 15 minute pulse, Figure 2D and
32 Supplementary Figure S2E, respectively) and found that as expected, mRNAs are
33 significantly more often stabilized in miRNA depleted mESCs relative to control.
34 Finally, and consistent with a role of miRNA in controlling the observed differences in

1 degradation rates, transcripts whose decay rates are significantly decreased, following
2 miRNA depletion, have a significantly higher density of miRISC clusters (10 and 15
3 minute pulse, Figure 2E and Supplementary Figure S2F, respectively).

4 In contrast with mRNAs and in line with the observed changes in steady state
5 abundances, we found that the degradation rates of cytosolic lncRNAs are minimally
6 impacted by miRNA depletion, with only a few displaying significant differences in
7 degradation rate (10 and 15 minutes pulse, Figure 2D and Supplementary Figure 2E).
8 Specifically, most cytosolic lncRNAs behave similarly to nuclear lncRNAs (10 and 15
9 minutes pulse, Figure 2F and Supplementary Figure 2G, respectively). The decrease
10 in degradation rate between wild-type and miRNA depleted cells is likely to be, at least
11 in part a consequence of well described compensation mechanisms [37-39] to account
12 for decreased synthesis rates between the two cell types (Supplementary Figure
13 S2H). The analysis of steady-state abundance and degradation rates following loss of
14 *Dicer* function indicate that, in contrast with coding transcripts, cytosolic lncRNAs are
15 resilient to miRNA-mediated destabilization.

16

17 **Micropeptide encoding transcripts undergo miRNA dependent destabilization**

18 Next, since our analysis of ribosomal profiling data indicated that a small fraction of
19 cytosolic lncRNAs is ribosome-bound (Figure 1A), we investigated whether
20 association with translating ribosomes would contribute to the impact of miRNAs on
21 the degradation rates of some cytosolic lncRNAs. As expected, mRNAs are
22 significantly more efficiently translated than lncRNAs but interestingly, the translation
23 efficiency of cytosolic lncRNAs, as a class, is significantly higher than that of nuclear
24 lncRNAs indicating that some might encode micropeptides (Figure 3A). The short
25 open reading frames of micropeptide encoding transcripts are often missed by coding
26 potential calculators leading to the misclassification of these transcripts as lncRNAs
27 [40]. To distinguish *bonafide* lncRNAs from micropeptide encoding transcripts we used
28 phyloCSF [41] and identified 59 cytosolic transcripts containing mammalian conserved
29 short open reading frames (median longest predicted ORF length 216 nucleotides,
30 Supplementary Table S1). These transcripts are almost 3 times more likely to be
31 bound by ribosomes than are other cytosolic lncRNAs (Figure 3B) and their translation
32 efficiency is significantly higher than that of cytosolic lncRNAs ($p < 6 \times 10^{-5}$, two-tailed
33 Mann-Whitney *U* test, Figure 3C) and more similar to that of mRNAs ($p < 1 \times 10^{-4}$, two-
34 tailed Mann-Whitney *U* test, Figure 3C) consistent with some of these transcripts

1 encoding micropeptides. We separated micropeptides from *bona fide* cytosolic
2 lncRNAs and found that fold change in degradation rate of micropeptides in miRNA
3 depleted cells relative to control, is similar to what is obtained for mRNAs and
4 significantly different from what is observed for *bonafide* lncRNAs (Figure 3D)
5 indicating further the requirement of translation for miRNA-dependent transcript
6 destabilization.

7

8 **miRNA impact coding but not noncoding transcript stability**

9 Our transcriptome wide analysis indicates that translation is required for miRNA
10 dependent target destabilization. To test this hypothesis, we selected one cytosolic
11 lncRNA (TCONS_00034281, Supplementary Figure S3A, hereafter lncRNA-c1) that
12 is relatively highly expressed in mESCs (Supplementary Figure S3B). Quantitative
13 PCR analysis supported that as indicated by the transcriptome wide profiling
14 (Supplementary Figure S3C), the steady state abundance of *lncRNA-c1* does not
15 increase upon miRNA depletion, as would be expected for *bonafide* miRNA target
16 such as *Lats2* or *Cdkn1A* [35] (Supplementary Figure S3D). Furthermore, and in
17 contrast with *Lats2* or *Cdkn1A*, *lncRNA-c1*'s stability is also not significantly affected
18 in cells lacking DICER function (Supplementary Figure S3E). This is despite, lncRNA-
19 c1 cytosolic localization (Supplementary Figure S3F) and binding by AGO2 that was
20 suggested by AGO2-CLIP data and confirmed by AGO2-RIP (Supplementary Figure
21 S3G-H).

22 We reasoned that if translation is required for miRNA-dependent transcript
23 destabilization, forcing association of a lncRNA candidate to translating ribosomes, by
24 fusing it downstream of a functional open-reading frame, should result in miRNA-
25 dependent degradation of the fused transcript (Figure 4A). We cloned *lncRNA-c1*
26 downstream of the Enhanced Green Fluorescent Protein stop codon (hereafter *GFP-*
27 *lncRNA-c1*) and transfected this construct into wild-type and miRNA depleted mESCs
28 (8 days after induction of *Dicer* loss of function). As controls, we transfected *GFP* and
29 *lncRNA-c1* expressing constructs. As expected, the expression of *lncRNA-c1* and
30 *GFP* is more similar between wild-type and miRNA-depleted cells than is the
31 expression of *GFP-lncRNA-c1*, whose levels significantly increase in miRNA depleted
32 cells (paired two-tailed t-test p-value < 0.02, Figure 4B), consistent with its miRNA
33 dependent destabilization in wild-type cells. If association with the translation
34 machinery is sufficient to induce miRNA-dependent decay of a miRISC-bound

1 noncoding transcript, one would expect introduction of a missense mutation in a
2 protein-coding miRNA target to decrease its miRNA-induced decay. Indeed,
3 introduction of a missense mutation disrupting the *Cdkn1a* start codon
4 (Supplementary Figure S4A-C) significantly decreases mutant *Cdkn1a* Δ ATG levels in
5 miRNA depleted mESCs (paired one-tailed t-test p-value < 0.05, Figure 4C).
6 Given that all constructs are under the control of the same promoter (T7), this increase
7 is likely a consequence of increased stability, as confirmed by qPCR analysis following
8 8h of transcription inhibition through actinomycin-D treatment (paired two-tailed t-test
9 p-value < 0.05, Supplementary Figure S4D).
10 *LncRNA-c1* is a predicted target of the miR-290/295 family (Supplementary Figure
11 S4E). To validate that these miRNAs are indeed contributing to miRNA-dependent
12 repression of *GFP-IncRNA-c1*, we co-transfected mESCs with *GFP-IncRNA-c1*
13 expressing vector and miR-294-inhibitors. We note a significantly higher expression
14 of *GFP-IncRNA-c1* in the inhibitor transfected cells compared to cells transfected with
15 negative control (unpaired two t-test p-value < 0.001, Figure 4D). We used site-
16 directed mutagenesis to mutate three miRNA recognition elements (MREs) for highly
17 expressed miRNAs within *GFP-IncRNA-c1* (hereafter *GFP-IncRNA-c1* Δ MRE). As
18 expected, reintroduction of miRNA mimics in DICER depleted mESC impacts the
19 levels of wild-type *GFP-IncRNA-c1* more than it does levels of *GFP-IncRNA-c1* Δ MRE
20 (paired one-tailed t-test p-value<0.05, Supplementary Figure S4F). The levels of
21 *GFP-IncRNA-c1* in wild-type mESC is also significantly lower than the level of *GFP-*
22 *IncRNA-c1* Δ MRE (paired t-test p-value<0.05, Supplementary Figure S4G). These
23 results are consistent with these MREs' contribution to wild-type *GFP-IncRNA-c1*
24 miRNA-dependent repression. Therefore, and as expected, the relative increase of
25 *GFP-IncRNA-c1* levels in miRNA depleted mESCs relative to wild-type mESC is
26 significantly higher than the increase in levels of *GFP-IncRNA-c1* Δ MRE (paired two
27 tailed t-test p-value < 0.05, Figure 4E). The presence of MRE for other mESC
28 expressed miRNA (Supplementary Table S2) is likely to explain why mutation of
29 miR290/295 MRE alone is not sufficient to entirely block miRNA-dependent *GFP-*
30 *IncRNA-c1* destabilization.
31 We conclude that association with translating ribosomes is required for miRNA-
32 dependent transcript destabilization and that noncoding transcripts are bound but not
33 post-transcriptionally regulated by miRNAs.

1 CONCLUSION

2

3 Posttranscriptional regulation by miRNAs leads to translational inhibition or transcript
4 destabilization [6]. Whereas the general consensus is that most miRNA-induced
5 changes can be explained by transcript destabilization [9, 10], increasing evidence
6 suggests that miRNA-dependent mRNA decay occurs co-translationally [13-22],
7 raising questions about the ability of miRNAs to posttranscriptionally regulate the
8 levels of noncoding transcripts.

9 Supporting different outcomes upon miRISC binding to coding and noncoding
10 transcripts, is recent evidence that these two classes of transcripts have distinct
11 interaction dynamics with processing bodies (PB) [42], the subcellular compartment
12 where miRNA-dependent destabilization is thought to occur [43]. Specifically, and in
13 contrast with miRNA-bound mRNAs, which localise to the core of PB, miRNA-bound
14 lncRNAs interact transiently and tend to locate to the PB periphery, a pattern that might
15 reflect missing interactions with other molecular factors involved in miRNA-dependent
16 regulation [42]. One such factor could be DDX6, a PB localised dead box helicase that
17 links miRNA-dependent translation inhibition and decay [44-46]. In mESCs, loss of
18 DDX6 function phenocopies loss of miRNA biogenesis [10, 47], suggesting that
19 molecular factors that couple translation with RNA decay, like DDX6, are required for
20 miRNA-dependent transcript destabilization.

21 These observations are surprising in light of previous analysis demonstrating efficient
22 miRNA dependent decay in the absence of translation initiation or elongation [23-25].
23 One potential confounder of previous studies is that they rely on the use of exogenous
24 reporters, which may not faithfully recapitulate what happens to endogenously
25 expressed miRNA targets. Cytosolic *bonafide* lncRNAs, that have been previously
26 shown to interact with miRISC [27] but not with the translation machinery [26], provide
27 a unique opportunity to investigate the requirement of translation to endogenous
28 miRNA-directed target decay.

29 Our transcriptome wide analysis following miRNA loss revealed, that in contrast with
30 mRNA, cytosolic lncRNA's steady state abundance significantly decreases in miRNA
31 depleted cells, suggesting this class of transcripts is not efficiently posttranscriptionally
32 regulated by miRNAs. To assess the direct impact of miRNA regulation on cytosolic
33 lncRNAs, we investigated, using RNA metabolic labelling, differences in the
34 degradation rates of these transcripts in wild-type and miRNA-depleted cells. This

1 analysis revealed that cytosolic lncRNAs degradation rates decrease less than the
2 degradation rates of mRNAs and to a similar extent as the degradation rates of nuclear
3 lncRNAs, that are not expected to be regulated by miRNAs. The decrease of lncRNA
4 degradation rates in miRNA depleted cells is likely the result of coupling between RNA
5 synthesis and decay which has been proposed as a mechanism to ensure gene
6 expression homeostasis [37-39]. While the decrease in degradation rates is a general
7 phenomenon in miRNA-depleted mESCs (Supplementary Figure 2H), the increased
8 stabilization of coding transcripts in near-absence of miRNA is likely to obscure such
9 effects for mRNAs.

10 Finally, we show that the stabilities of putative micropetides and mRNAs are similarly
11 impacted by miRNAs, further supporting the requirement of translation for miRNA
12 dependent regulation of endogenously expressed transcripts.

13 To validate this hypothesis, we selected one cytosolic lncRNA, bound by AGO2 and
14 with functional binding sites for miR-290/5 family, and forced its association to
15 translating ribosomes by cloning it downstream of a functional protein-coding open
16 reading frame. Consistent with the requirement of translation for miRNA-dependent
17 transcript destabilization, forcing association to the ribosomes results in miRNA-
18 dependent posttranscriptional regulation of previously unaffected transcripts. These
19 results are unlikely a consequence of pleiotropic effects of loss of miRNA function as
20 mutation of the functional MREs within candidate lncRNA sequence reduces the
21 impact of miRNAs on candidate expression. We conclude that miRNA-dependent
22 regulation of endogenously expressed transcripts requires translation.

23 The requirement of translation for miRNA dependent regulation indicates that despite
24 extensive evidence for miRISC binding to cytosolic lncRNAs, the levels of these
25 noncoding transcripts are not posttranscriptionally modulated by miRNA. Evidence
26 that miRNA binding sites within lncRNAs evolved under constraint [28] suggests that
27 miRNA-lncRNA interactions are biologically relevant. One possibility, is that such
28 interactions reflect miRNA-dependent regulation by lncRNAs. A number of examples
29 support these roles in the context of disease and development [48-50]. Previous
30 analysis of the potential extent of such regulatory roles by miRNAs suggested this
31 mechanism of lncRNA function is prevalent among cytosolic transcripts [28]. However,
32 given the relatively low abundance of most lncRNAs, which rarely exceeds the
33 expected threshold to exert significant and physiological relevant changes in miRNA
34 targets [51-53] the biological relevance of miRNA dependent regulation by lncRNAs

1 remains controversial. In light of the present results, that support a different outcome
2 of miRNA interactions with mRNA or lncRNAs, further experiments are now needed
3 to assess the generality of mRNA-based conclusions.

4 More generally the present results also imply that miRISC binding, per se, is not
5 sufficient to determine the outcome of bound targets suggesting the requirement of
6 further yet unidentified molecular partners.

7 In summary, the analysis of endogenously expressed and miRISC bound noncoding
8 transcripts provides further evidence that translation is indispensable for miRNA-
9 dependent regulation of endogenous transcripts, suggesting the requirement of further
10 molecular partners and highlighting differences in posttranscriptional regulation of
11 coding and noncoding RNAs.

12

13

14

1 **METHODS**

2

3 **KEY RESOURCES TABLE**

4

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Rabbit anti-AGO2	Cell Signaling	#2897
normal rabbit IgGs	SIGMA	I5006
Rabbit anti-DICER	SIGMA,	SAB4200087
anti-Rabbit IgG-HRP	Cell Signaling,	#7074
Mouse anti-AGO2	FujiFilm Wako P.C. Corp.	018-22021
Rabbit anti-DCR	Santa Cruz Biotechnology	H-212: sc-30226
Rabbit anti-NANOG	Abcam	Ab70482
Rabbit anti-OCT4	Abcam	Ab27985
Mouse anti-ACTIN- β	SIGMA	A2228-100UL
Goat Anti-Rabbit IgG (H+L)	BIORAD	170-6515
Goat Anti-Mouse IgG (H+L)	BIORAD	170-6516
Rabbit Anti-Goat IgG/HRP	Dako (Agilent)	P0449
Chemicals, Peptides, and Recombinant Proteins		
[Z]-4-Hydroxytamoxifen	Sigma	H7904
β -mercaptoethanol	Thermo Fischer	31350-10
Recombinant mouse Leukemia Inhibitory factor	Merck	ESG1107
4sU	Sigma	T4509
biotin-HPDP	Thermo Fisher	21341
TURBO DNase	Thermo Fisher	AM2238
Actinomycin D	Thermo Fischer	11805017
protease inhibitors	Roche	11697498001
RNase inhibitors	Thermo Fischer	EO0381
DNase	Promega	M6101
Tris Base	Applichem	A1379, 1000
NaCl	Applichem	A2942, 1000
Glycine	Applichem	A1067, 1000
SDS	Applichem	A2263, 0100
Methanol	SIGMA	32213,1L
Hydrochloric Acid fuming 37%	ROTH	4625.1
Phenol-chloroform-Isoamyl alcohol mixture	SIGMA	77618-500ML
Chloroform	SIGMA	C2432-500ML
Sodium-Azide	SIGMA	S2002
Ponceau S Solution	SIGMA	P7170
NheI-HF	NEB	R3131S
XhoI	NEB	R0146S
EcoRI-HF	NEB	R3101S
Dpni	NEB	R0176S
T4 DNA ligase	NEB	M0202S

Critical Commercial Assays		
DNase on column digestion	Qiagen	74104
TruSeq small RNA Library Prep kit	Illumina	NA
Qiagen RNeasy Mini Kit	Qiagen	74104
Ovation RNA-Seq System V2	Tecan Genomics	7102-08
TruSeq Nano DNA Low Throughput Library Prep Kit	Illumina	20015964
PARIS kit	Thermo Fisher	AM1921
miRNeasy kit	Qiagen	217004
Quantitect Reverse Transcription Kit	Qiagen	205310
FastStart DNA Essential DNA Green Master	Roche	06924204001
Applied Biosystems Taqman microRNA Reverse Transcription Kit	Thermo Fischer	4366596
Taqman Universal Master Mix II	Thermo Fischer	4440043
GoScript RT Kit	Promega	A5004
SuperSignal West kit	Thermo Scientific	34095
Infusion HD Cloning kit	Takara	121416
Deposited Data		
mESC small RNA seq	This paper	GEO: GSE143277
mESC 4sU-seq	This paper	GEO: GSE143277
mESC AGO2-CLIP	Leug, KLA, et al, 2011	GEO: GSE25310
mESC Ribosomal Profiling	Ingolia, N et al, 2011	GEO: GSE30839
Experimental Models: Cell Lines		
Mouse DTCM23/49 XY embryonic stem cells	Graham B. et al, 2016	N/A
Mouse ESCs (E14Tg2a)	ATCC	CRL-1821
Oligonucleotides		
Primers sequences, see Supplementary Table S3	This paper	N/A
mmu-miRNA294-3p inhibitors	Thermo Fisher	MH10865
mmu-miR294-3p mimics	Thermo Fisher	MC10865
mmu-miR295-3p mimics	Thermo Fisher	MC10386
miRNA mimic negative controls	Thermo Fisher	4464059
mmu-miR-290-3p Taqman probe	Thermo Fisher	002591
mmu-miR-295-3p Taqman probe	Thermo Fisher	000189
snoRNA202	Thermo Fisher	001232
Recombinant DNA		
pcDNA3.1(-) plasmid	Addgene	V79520
Software and Algorithms		
Cutadapt	Martin, M, 2011	DOI:10.14806/ej.17.1.200 .

STAR	Dobin, A et al, 2013	https://github.com/alexdobin/STAR
RSEM	Bo, L, et al, 2011	http://deweylab.biostat.wisc.edu/rsem
INSPEcT	De Pretis, S et al, 2015	https://bioconductor.org/packages/release/bioc/html/INSPEcT.html
Bowtie	Langmead, B, et al, 2009	http://bowtie-bio.sourceforge.net/index.shtml
PARalyzer	Corcoran, D et al, 2011	https://ohlerlab.mdc-berlin.de/software/PARalyzer_85/
BEDtools	Quinlan, AR, et al, 2010	https://bedtools.readthedocs.io/en/latest/
Bowtie 2	Langmead B et al, 2012	http://bowtie-bio.sourceforge.net/bowtie2/index.shtml
edgeR	Robinson, M et al, 2010	https://bioconductor.org/packages/release/bioc/html/edgeR.html
Other		
DMEM culture medium	Thermo Fischer	41965-039
100 X Non-Essential Amino Acids	Thermo Fischer	11140-035
Fetal Bovine Serum	Thermo Fischer	10499-044
Penicillin/Streptomycin	Thermo Fischer	15140122
Trizol	Thermo Fisher	15596-026
Dynabeads™ MyOne™ Streptavidin T1 beads	Thermo Fischer	65601
DynaMag™-2 Magnetic stand	Thermo Fisher	12321D
lipofectamine 2000	Thermo Fisher	12566014
RNAimax transfection reagent	Thermo Fisher	13778150
Protein A/G Plus-Agarose beads	Santa Cruz Biotechnology	sc-2003
Qiagen 2 ml phase lock tubes	Qiagen	129056
Qiagen 15 ml phase lock tubes	Qiagen	129065
NuPage™ 12% Bis-Tris Gel	Thermo Fisher	NP0341BOX
Advansta ECL Western Bright	Advansta	K-12045-D20
10 X Cutsmart Buffer	NEB	B7204S
10 X T4 DNA ligase Buffer	NEB	B0202S

1

2 **Mouse embryonic stem cell culture**

1 Feeder depleted mouse DTCM23/49 XY embryonic stem cells [28, 32, 54] were grown
2 on 0.1% gelatin-coated tissue culture treated plates in a humidified incubator with 5%
3 (v/v) CO₂ at 37°C in 1X DMEM medium supplemented with 1x Non-Essential Amino
4 Acids, 50 uM β-mercaptoethanol, 15% Fetal Bovine Serum, 1%
5 Penicillin/Streptomycin, and 0.01% of Recombinant mouse Leukemia Inhibitory factor.
6 Cultures were maintained by passaging cells every 48 hours (replating density ~
7 3.8*10⁴ cells/cm²). Unless stated otherwise, to induce loss of *Dicer* function, cells were
8 cultured in mESC growth media supplemented with 800 nM tamoxifen previously
9 resuspended in 100% ethanol ([Z]-4-Hydroxytamoxifen [4-OHT]) for 48h.
10 Subsequently, cells were transferred to non-supplemented mESC growth medium and
11 cultured for 6 additional days.

12 WT E14 mESC line (129/Ola background) was cultured in Dulbecco's Modified Eagle
13 Media (DMEM), containing 15% of fetal bovine serum, 100 U/mL LIF, 0.1 mM 2-β-
14 mercaptoethanol and 1% Penicillin/Streptomycin, on 0.2% gelatin-coated plates in
15 absence of feeder cells. The culture medium was changed daily and cells were grown
16 at 37°C in 8% CO₂

17

18 **Small RNA extraction in *Dicer* depletion timecourse.**

19 Feeder depleted mouse DTCM23/49 XY embryonic stem cells were cultured in mESC
20 growth media supplemented with 800 nM tamoxifen 4-OHT. Small RNA extraction and
21 DNase treatment following 0, 4, 8, 10 and 12 days of 4-OHT treatment was performed
22 using the Qiagen miRNEasy Mini Kit and Qiagen RNase free DNase according to
23 manufacturer instructions.

24

25 **Small RNA sequencing, mapping and quantification.**

26 Small RNA libraries were prepared from 500 ng of total RNA using Illumina TruSeq
27 small RNA protocol and sequenced on Illumina HiSeq 2500.

28 Sequencing adapters were removed from fifty nucleotides long single-end reads using
29 cutadapt (v1.8) and mapped to mouse genome (mm10) using bowtie2 (v2.2.4). Gene
30 expression levels for all mouse miRNAs annotated in miRbase (v21) [55] were

1 quantified using HT-seq (v0.6.1). The raw sequencing data and reads counts are
2 available on the NCBI Gene Expression Omnibus (GEO) under accession number
3 GSE143277.

4

5 **Western blot**

6 Approximately 500,000 mESCs were harvested and washed twice with ice-cold PBS
7 and stored, after PBS removal, at -80 °C until lysis. Cells were incubated in 50 µl of
8 cold RIPA Buffer (150 mM NaCl, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1% SDS,
9 50 mM Tris, pH 8.0) on a rotating wheel for 1 hour at 4°C. Protein concentration was
10 determined using the Pierce BCA Protein Assay kit according to manufacturer's
11 instructions.

12 30 µl of protein was separated on NuPage™ 12% Bis-Tris gel and transferred
13 overnight at 4°C in transfer buffer (25 mM Tris-HCl pH7.6 192 mM glycine, 20%
14 Methanol) on to nitrocellulose membranes. Transfer efficiency was assessed by
15 staining the membrane with Ponceau S solution and staining solution was removed
16 by washing the membrane 3 times with TBS-T (Tris-buffered saline, 0.1% Tween 20,
17 5 minutes, room temperature) After incubation with 5% skim milk in TBS-T for 4-6
18 hours at 4°C, the membranes were washed once in TBS-T and incubated with anti-
19 DICER (1:3000), anti-NANOG (1:1000) or Anti-OCT4 (dilution 1:1000) antibodies in
20 5% skim milk in TBS-T overnight at 4°C on a see-saw shaker. After probing for protein
21 of interest, membranes were stripped and probed for ACTIN-B as a loading control:
22 Anti-ACTB (1:10000 dilution in 5% skim milk in TBS-T) Membranes were incubated
23 with Secondary antibodies (DICER= 1:3000 Goat Anti-Rabbit IgG (H+L)-HRP
24 Conjugate; for NANOG= 1:4000 Goat Anti-Rabbit IgG (H+L)-HRP Conjugate; for
25 OCT4=1:2500 Rabbit Anti-Goat IgG/HRP, for ACTIN-B=1:2000 Goat Anti-Mouse IgG
26 (H+L)) in 5% skim milk in TBS- for 1h at room-temperature. Immunoblots were
27 developed using the WesternBright ECL premixed Peroxide and ECL solutions and
28 detected using an imaging system (Vilber Fusion Chemiluminescence).

29 Following detection, secondary antibody coupled with the HRP was deactivated by
30 washing the membrane two times for 20 minutes with 1% (w/v) Sodium-Azide in TBS-
31 T and the membrane incubated two hours at 4 °C with 5% (w/v) skimmed milk in TBST

1 containing primary antibody for the ACTIN- β loading control (1:4000). The membranes
2 were washed three times for 15 minutes in fresh TBS-T and incubated for one hour at
3 room temperature with the secondary antibody coupled with horseradish peroxidase
4 in 5% skimmed milk in TBS-T (for ACTIN- β = 1:4000 Goat Anti-mouse IgG). Washing
5 and protein detection were performed as previously described.

6

7 **Cell proliferation assay**

8 16-24 hours prior to DNA staining, 33,000 cells/cm² were plated on a 6-well gelatin-
9 coated tissue culture plate. Edu (Click-iT Edu Alexa Fluor™ 488 Flow Cytometry
10 Assay Kit) was added to mESCs growth medium to a final concentration of 10 μ M, and
11 the cells incubated at 37 °C for 30 minutes. Cells were trypsinized, counted and, for
12 each tested sample, 750,000 cells were washed once with 3 ml of 1% BSA in PBS,
13 resuspended in 100 μ l of Click-iT fixative buffer and incubated for 15 minutes at room
14 temperature in the dark. Cells were washed with 3 ml of 1%BSA in PBS, centrifuged
15 and the supernatant removed. The pellet was resuspended in 100 μ l of 1X Click-iT
16 saponin-based permeabilization and wash reagent, and the cells incubated for 15
17 minutes at room temperature in the dark. 500 μ l of freshly prepared Click-iT reaction
18 cocktail containing Alexa Fluor 488 Fluorescent dye Azide was added to the
19 permeabilized cells in 1X Click-iT saponin-based permeabilization and wash reagent
20 and the mix incubated at room temperature in the dark for 30 minutes. Cells were
21 washed once with 3 ml of 1X Click-iT saponin-based permeabilization and wash
22 reagent and following supernatant removal resuspended in 500 μ l of Click-iT saponin-
23 based permeabilization and wash reagent. Cells were analyzed by flow cytometry on
24 a Beckman Coulter Gallios Flow Cytometer according to manufacturer's instructions,
25 using a 488 nm excitation wavelength and a green emission filter (530/30 nm).

26

27 **4sU metabolic labelling**

28 Five million DTCM23/49 XY mESCs (WT and miRNA depleted) were seeded and
29 allowed to grow to 70-80% confluency (approximately 1 day). 4sU was added to the
30 growth medium (final concentration of 200 μ M) and cells were incubated at 37 °C for
31 10 or 15 minutes. RNA was extracted using Trizol, according to manufacturer

1 instructions and DNase treated using RNeasy on column digestion according to
2 manufacturer's instructions. 100 µg of RNA was incubated for 2 h at room temperature
3 with rotation in 1/10 volume of 10X biotinylation buffer (Tris-HCl pH 7.4, 10 mM EDTA)
4 and 2/10 volume of biotin-HPDP (1mg/ml in Dimethylformamide). Following
5 biotinylation, total RNA was purified through phenol:chloroform:isoamyl alcohol
6 extraction and precipitated with equal volume of Isopropanol and 1/10 volume of 5M
7 NaCl. RNA was washed once with 75% Ethanol and resuspended in DEPC-treated
8 H₂O. Equal volume of biotinylated RNA and pre-washed Dynabeads™ MyOne™
9 Streptavidin T1 beads were mixed and incubated at room temperature for 15 minutes
10 under rotation. The beads were then separated using a DynaMag™-2 Magnetic stand.
11 The supernatant (that contains unlabeled preexisting RNA) was placed at 4°C until
12 precipitation. Beads were washed and biotinylated RNA dissociated from streptavidin
13 coated beads by treatment with 100 mM 1,4-Dithiothreitol for 1 minute, followed by 5
14 minutes in RTL buffer. Beads were separated from the solution using DynaMag™-2
15 Magnetic stand and the RNA recovered from the supernatant extracted using Qiagen
16 RNeasy Mini Kit according to the manufacturer's instructions. Preexisting RNA was
17 precipitated with equal volume of Isopropanol and centrifuged for 45 minutes at 15
18 000 g at 4°C. Preexisting RNA pellet was washed with 75% Ethanol and resuspended
19 in DEPC-treated H₂O. Metabolic labelling experiments were repeated once for the 2
20 labelling durations (2 biological replicates).

21

22 **RNA sequencing, mapping, and quantification of metabolic rates**

23 Total RNA libraries were prepared from 10 ng of DNase-treated preexisting and newly
24 transcribed RNA using Ovation® RNA-Seq and sequenced on an Illumina HiSeq 2500
25 (average of fifty million reads per library).

26 Hundred nucleotides long single-end reads were first mapped to *Mus musculus*
27 ribosomal RNA (rRNA, ENSEMBL v91,[62]) with STAR v2.5.0 [56]. Reads that do not
28 map to ribosomal RNA were then aligned to intronic and exonic sequences of *Mus*
29 *musculus* transcripts database (ENSEMBL v91) using STAR and quantified using
30 RSEM [57]. Principal Component Analysis (PCA) of read counts was performed to
31 demonstrate separation between newly-transcribed (labeled) and total RNA (Figure

1 S1D). Rates were inferred, independently at each labeling point using the INSPEcT
2 ([35] Bioconductor package v1.8.0). Specifically, the absolute values of synthesis,
3 processing and degradation rates in each condition were estimated using the
4 'newINSPEcT' function with the option pre-existing=TRUE, while the statistical
5 significance of the variation of the rates between conditions was obtained using the
6 method 'compareSteady' [see INSPEcT vignette at
7 <http://bioconductor.org/packages/INSPEcT/>]. The raw sequencing data is available on
8 the NCBI Gene Expression Omnibus (GEO) under accession number GSE143277.

9 **Identification of AGO2 bound regions in mESCs**

10 Cutadapt [58] was used to remove sequence adapters from publicly available AGO2-
11 CLIP sequencing reads from wild-type and *Dicer* mutant mESCs [30]. Trimmed reads
12 were mapped to the mouse genome (mm10) using bowtie [59] (bowtie -v 2 -m 10 --
13 best -strata) as previously described [60]. Mapped reads from the same cell type were
14 merged AGO2 bound clusters identified using PARAlyzer v1.5 (Bandwidth=3;
15 minimum read count per group=5; minimum read count per cluster=1; minimum read
16 count for KDE=5; minimum cluster size=1; minimum conversion count per cluster=1;
17 minimum read count for cluster inclusion=1) [60]. Clusters present in wild-type and
18 DICER null cells were excluded using BEDtools [61].

19

20 **Translational efficiency**

21 Ribosome profiling (RP) and total RNA raw reads were downloaded from SRA
22 database (SRX084815 and SRX084812, respectively [29]). Reads were trimmed
23 based on quality and sequence adapters removed with Cutadapt (v. 1.8,[58]). Only
24 reads with the expected read length (16 to 35 nt for the ribosome footprint and 35 to
25 60 nt for total RNA) were kept for further analysis. Reads mapping *Mus musculus*
26 ribosomal RNA (rRNA) and transfer RNA (tRNA) databases (ENSEMBL v91,[62])
27 using to bowtie2 (v. 2.3.4.1, parameters: -L 15 -k 20,[63]) were excluded. The
28 remaining reads (SRX084815: 12 228 002 reads; SRX084812: 12 361 681 reads)
29 were aligned against *Mus musculus* transcripts database (ENSEMBL v91) using
30 bowtie2 (v. 2.3.4.1, -L 15 -k 20). Multi-mapping reads (mapping to 2 or more transcripts
31 from different gene loci) were filtered out and the remaining reads summarised at a
32 gene level using an in-house script. Translational efficiency (TE) was calculated in R.
33 Briefly, raw genes ribosome footprints and total RNA counts were normalized using

1 the edgeR package to account for variable library depths (cpm function ;
2 [64]). Translational efficiency (TE) was calculated as the log₂ ratio between normalized
3 RP counts and normalized TR counts.

4 Conserved short open reading frames within lncRNA transcripts were identified by
5 overlapping lncRNA loci with regions with positive phyloCSF scores, those that likely
6 represent conserved coding regions, in any of the three possible reading frames on
7 the same strand as the lncRNA transcript ([41]). lncRNA transcripts containing
8 conserved short open reading frames are likely to encode micropeptides.

9

10 **Subcellular Fractionation**

11 Subcellular fractionation of mESCs was carried out using the PARIS kit according to
12 the manufacturer's instructions. Following RNA extraction from cytosolic and nuclear
13 fractions, genomic DNA was removed from samples using TURBO DNase. DNase
14 treated RNA was extracted using phenol chloroform and RNA precipitated using
15 equal volume of isopropanol and 1/10 volume of 5M NaCl. RNA pellet was washed
16 with 75% Ethanol and resuspended in DEPC-treated H₂O.

17

18 **RNA extraction and qPCR**

19 Total cellular RNA was extracted with the RNeasy Mini kit according to the
20 manufacturer's instructions. To quantify levels of mature miRNAs, total RNA was
21 extracted with the miRNeasy kit. Genomic DNA was removed by performing an on
22 column DNase treatment according to manufacturer's instructions. Following RNA
23 elution in DEPC-H₂O, an additional DNase treatment was performed using TURBO
24 DNase as described above. Following precipitation, RNA was reverse transcribed
25 using the Quantitect Reverse Transcription Kit. Quantitative PCR reactions were
26 prepared using the FastStart DNA Essential DNA Green Master and sequence-
27 specific primers (Supplementary Table S3 and analyzed using a Roche Light
28 Cycler®96. Unless otherwise stated *Actin-β* and *Polymerase II* were used as internal
29 controls.

30 For miRNA level quantification, RNA was reverse transcribed using the Applied
31 Biosystems Taqman microRNA Reverse Transcription Kit and small RNA specific
32 probes according to manufacturer's protocol. Small RNA expression levels relative to
33 *small nucleolar RNA 202* (sno-202) were subsequently quantified on a Roche Light

1 Cycler®96 using the Taqman Universal Master Mix II, no UNG, according to
2 manufacturer's instructions.

3

4 **RNA stability**

5 Transcription was inhibited by adding Actinomycin D resuspended in Dimethyl
6 Sulfoxide at a final concentration of 10 µg/ml in supplemented mESC growth medium.
7 Stability of transcripts was inferred by comparing relative gene expression levels
8 (normalized to *Actin-β*) in cells incubated for 8 hours with Actinomycin-D and untreated
9 cells.

10

11 **Candidate lncRNA and mRNA analysis**

12 Enhanced Green Fluorescent Protein gene (see Supplementary Table S3) was
13 amplified from the pBS-U6-CMV-EGFP plasmid [65] with primers complementary to
14 EGFP and NheI restriction sites (see Supplementary Table S3) and inserted into
15 NheI digested pcDNA3.1(-)(Addgene, V79520). Ligation was performed using T4
16 DNA ligase according to manufacturer instructions. Plasmid was transformed into
17 DH5α subcloning efficiency bacterial cells and Sanger sequencing was used to
18 confirm correct orientation of EGFP insertion into plasmid (*GFP*).

19

20 *lncRNA-c1* was amplified from mESC cDNA using sequence specific primers with
21 overhangs containing restriction sites for either XhoI or EcoRI (Supplementary
22 Table S3) and cloned directionally into XhoI-EcoRI digested pcDNA3.1(-) plasmid
23 to generate *lncRNA-c1* construct downstream of T7 promoter. Ligation was
24 performed using T4 DNA ligase according to manufacturer instructions. *GFP-*
25 *lncRNA-c1* construct was generated adopting same cloning strategy but inserting
26 *lncRNA-c1* into *GFP* construct. Sanger sequencing was used to confirm correct
27 sequence.

28 *Cdkn1a* was amplified from mESC cDNA using sequence specific primers with
29 overhangs containing restriction sites for either XhoI or EcoRI (Supplementary

1 Table S3) and cloned directionally into XhoI-EcoRI digested pcDNA3.1(-) plasmid
2 downstream of T7 promoter. Forward primers *Cdkn1a*ΔATG introduce a missense
3 mutation that deletes the 1st position of the *Cdkn1a* start codon (Supplementary
4 Table S3). Ligation was performed as previously described and the correct
5 sequence of constructs was confirmed by Sanger sequencing.

6 2 MRE on *GFP-IncRNA-c1* were mutated using, the Takara In-fusion HD cloning kit
7 according to manufacturer's instructions. The primers were designed using the
8 manufacturer online design tool ([https://www.takarabio.com/learning-](https://www.takarabio.com/learning-centers/cloning/in-fusion-cloning-tools)
9 [centers/cloning/in-fusion-cloning-tools](https://www.takarabio.com/learning-centers/cloning/in-fusion-cloning-tools)) and are available in Supplementary Table
10 S3. The MREs were mutated sequentially using primer containing the mutation of
11 interest and AmpHiFi PCR Master Mix. PCR products were gel purified, ligated
12 using the In-fusion HD enzyme and transformed into Stellar competent bacterial
13 cells according to manufacturer' instruction. MRE mutation was confirmed through
14 Sanger sequencing.

15 1 MRE on *GFP-IncRNA-c1* was mutated using the Phusion High-Fidelity
16 Polymerase. Briefly, primers containing a scrambled sequence of the seed region
17 within the MRE and wings complementary to the targeted sequence (Supplementary
18 Table S3) were used to amplify from the *GFP-IncRNA-c1* containing plasmid.
19 Following amplification PCR purification was performed and DpnI digestion was
20 used to digest template plasmid. Blunt end ligation using T4 DNA ligase was
21 performed to ligate amplified sequence containing mutated MRE according to
22 manufacturer instructions. Ligated construct was subsequently transformed into
23 DH5α bacterial cells and MRE mutation was confirmed through Sanger sequencing.

24 One day prior to transfection wild-type and miRNA depleted DTCM23/49 XY
25 embryonic stem cells were plated in 10 cm dishes at a density of 35000 cells/cm².
26 Cells were transfected with 484x10⁻¹⁵ mol of candidate expressing vector using the
27 lipofectamine 2000 transfection reagent. RNA was extracted 24 hours after
28 transfection. Gene expression levels relative to *Actin-β* and *Polymerasell* of
29 transfected candidates were normalized to *Neomycin* expression to account for
30 differences in transfection efficiency between different cell types and experiments. To

1 distinguish between mRNA endogenous and exogenous expression, *Cdkn1a* levels
2 were measured using Bovine Growth Hormone (BGH) polyadenylation signal specific
3 primers (Supplementary Table S3) which bind upstream of the termination site of the
4 exogenously expressed *Cdkn1a* constructs.

5 For miRNA mimic and inhibitor transfections, mmu-miRNA294-3p inhibitors (30 mM),
6 mmu-miR294-3p, mmu-miR295-3p mimics (100 mM) and miRNA mimic negative
7 controls were transfected 24 hours after plasmid transfection using the RNAimax
8 transfection reagent according to manufacturer's instructions. RNA was extracted 24
9 hours after small RNA transfection and reverse transcription was performed according
10 to manufacturer's instructions as described above.

11 **RNA immunoprecipitation**

12 RNA immunoprecipitation was performed as previously described [66]. Briefly,
13 4.8×10^6 E14 WT cells were seeded into 10cm dishes 16 hours prior to harvest. At the
14 same time, 60 μ l of Protein A/G Plus-Agarose beads were incubated with 10 μ l of
15 Rabbit anti-AGO2 or 2.5 μ g of normal rabbit IgGs. Protein content in cell lysate was
16 split in half, adjusted to 1ml using IP Lysis buffer and supplemented with protease
17 inhibitors and RNase inhibitors. 50 μ l of diluted cell lysates were collected for Input
18 (5%). The remaining cell lysate was added to the A/B or IgG coupled beads and
19 incubated overnight at 4° C, on a rotating wheel. After washing, 100 μ l of RIP buffer +
20 1 μ l of RNase inhibitor was added to the beads and centrifuged. 20 μ l and 80 μ l of
21 supernatant were collected for protein and RNA analysis. Immunoprecipitated and
22 input RNA was extracted using TRIzol reagent, resuspended in DNase reaction mix
23 (16 μ l ddH₂O, 2 μ l 10x RQ1 DNase buffer, 2 μ l RQ1 DNase) and reverse transcribed
24 using the GoScript RT Kit and oligo d[T]₁₈. RT-qPCR were performed as described
25 above.

26 10 μ l of RIP supernatant and input samples were separated on 8% SDS-PAGE gels
27 and transferred to PVDF membranes. After incubation with 5% skim milk in
28 1xPBS/0.1% Tween-20, the membranes were washed and incubated with antibodies
29 against AGO2 (ARGONAUTE 2 Rabbit mAb) and Dicer (Rabbit anti-Dicer) at 4° C. for
30 16h. Secondary antibodies (anti-Rabbit IgG-HRP) were incubated on membranes for

1 1h at RT at a dilution of 1:5000. Immunoblots were developed using the SuperSignal
2 West kit and detected using an imaging system. Membrane stripping was performed
3 by low pH method and AGO2 membrane was re-probed with antibodies against AGO2
4 (Argonaute 2 Mouse mAb). All membranes were stained using a coomassie blue
5 staining solution to ensure equal loading.

6 7 **Data and Code Availability**

8 RNA sequencing data was analyzed as described in Method Details; the data files are
9 available in the Gene Expression Omnibus accession number GEO: GSE143277.
10 Unprocessed Western blot images are available at Supplementary File 1 and 2.

11 12 **Acknowledgements**

13 We would like to thank the Genomics Technology Facility at the University of
14 Lausanne for help with RNA integrity analysis, library preparation and sequencing.

15 We would like to thank Maria Ferreira Da Silva for performing the Flow Cytometry
16 analysis of the Proliferation Rate assay. The computations were performed at the
17 Center for high-performance computing of the University of Lausanne.

18 This work was funded by the Swiss National Science Foundation (grant
19 PP00P3_150667 to A.C.M and 31003A_173120 to C.C) and the NCCR in RNA &
20 Disease (A.C.M. and C.C.).

21 22 **Authors Contributions**

23 AB and ACM designed the study. AB, SdP, JYT, RD and ACM performed the *in silico*
24 analysis. AB, BA, HW, CC and ACM performed and analyzed *in vitro* experiments
25 analysis. MP, CC and ACM supervised the study. ACM wrote the manuscript. All
26 coauthors read and approved the manuscript.

27
28
29

1 Figure Legends

2

3 **Figure 1- Steady-state abundance of lncRNAs is not directly affected by miRNA**
4 **loss** (A) Percentage of mRNAs (n=6701, red) and predominantly cytosolic (n=57,
5 blue) and nuclear lncRNAs (n=175, grey) with experimental evidence of binding by
6 ribosomes (Translation Efficiency>0) in mESCs. (B) Density of AGO2 wild-type
7 specific clusters across cytosolic lncRNAs (n=48, blue) and the 3'untranslated regions
8 of mRNAs (n=2355, red) with experimental evidence for AGO2 binding in mESC (>0
9 AGO2 clusters). Small RNA and Poly(A)-selected RNA sequencing based estimates
10 of the fold difference (y-axis) in (C) miRNA and (D) mRNA expression, respectively,
11 relative to day 0, during a 12 days' time-course (x-axis) following treatment of
12 DTCM23/49XY mESC with 4-OHT and loss of DICER function. Points represent the
13 average miRNA or mRNA expression and error bars the standard deviation based on
14 3 independent biological replicates. (E) Cumulative distribution plot of the fold-
15 difference in expression after 8 days of tamoxifen treatment for mRNAs, expressed at
16 day 0 (tpm \geq 1) with (n=1612) and without (n=12301) AGO2 clusters. (F) Distribution of
17 the relative fold-change after 8 days of 4-OHT treatment in steady state abundance,
18 relative to day 0, for mESC expressed (tpm \geq 1) mRNAs (n=19306, red), cytosolic
19 (n=445, blue) and nuclear (n=529, grey) lncRNAs. Statistics: *-p<0.05, **-p<0.01 and
20 ***-p<0.001.

21

22 **Figure 2- No evidence for miRNA-dependent destabilization of cytosolic**
23 **lncRNAs** (A) Schematics of 4sU metabolic labelling of conditional *Dicer* knockout and
24 wildtype cells experiment. Correlation between degradation rates (log10) obtained
25 after 10 (x-axis) and 15 (y-axis) minutes of 4sU labelling in wildtype (B) and DICER
26 null (C) cells. (D) Volcano plot showing the adjusted p-value (y-axis) as a function of
27 the fold-change in degradation rate estimates, based on the 10 minutes pulse,
28 between KO and WT cells (x-axis) for protein-coding genes (red), cytosolic (blue) and
29 nuclear (grey) lncRNAs. Each point represents a transcript and horizontal dashed line
30 the significance cut-off. (E) Cumulative distribution plot of the density of AGO2 clusters
31 in the 3'untranslated regions of AGO2 bound mRNAs (AGO2 cluster>0) whose
32 degradation rates were either significantly (n=711, red) or not significantly changed
33 (n=1127, black) between KO and WT cells, based on the 10 minutes pulse estimates.
34 (F) Distribution of the fold-change after 8 days of tamoxifen treatment in degradation
35 rate (estimated based on the 10 minutes pulse) of mRNAs (n=29900, red), cytosolic
36 (n=474, blue) and nuclear (n=2348, grey) lncRNAs, in KO relative to WT cells.
37 Statistics: *-p<0.05, **-p<0.01 and ***-p<0.001.

38

39 **Figure 3- Micropeptide encoding transcript expression is posttranscriptionally**
40 **regulated by miRNAs.** (A) Distribution of the translational efficiency, in mESCs, of
41 mRNAs (n=7156, red), cytosolic (n=341, blue) and nuclear (n=1915, grey) lncRNAs.
42 (B) Fraction of cytosolic lncRNAs with experimental evidence for ribosomal binding
43 with (red) or without (blue) an overlapping conserved short open reading frame. (C)
44 Distribution of the translational efficiency, in mESCs, of mRNAs (n=7156, red),
45 micropeptide encoding transcripts (n=43, pink) and *bona fide* cytosolic (n=298, blue)
46 and nuclear (n=1857, grey) lncRNAs. (D) Distribution of the fold-change after 8 days
47 of 4-OHT treatment (KO) in degradation rates for mRNAs (n=13296, red),
48 micropeptide encoding transcripts (n=43, pink) and *bona fide* cytosolic (n=759, blue)
49 and nuclear (n=4299, grey) lncRNAs, relative to WT cells. Statistics: *-p<0.05, **-
50 p<0.01 and ***-p<0.001.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16

Figure 4- Association of lncRNA-c1 with translating ribosomes results in its miRNA-dependent decay. (A) Schematic of the construct tested in WT and miRNA depleted mESCs (B) Expression of *GFP*, *lncRNA-c1* and *GFP-lncRNA-c1* (x-axis) in miRNA depleted cells (KO) relative to WT mESC (y-axis) 24h hours post-transfection. (C) Expression of *Cdkn1a* and *Cdkn1a Δ ATG* (x-axis) in miRNA depleted cells (KO) relative to WT mESC (y-axis) 24h hours post-transfection. (D) *GFP-lncRNA-c1* expression 24 hours following transfection of mESCs with miRNA294-3p inhibitors or small RNA negative control. (E) Expression of *GFP-lncRNA-c1* and *GFP-lncRNA-c1 Δ MRE* (x-axis) in miRNA-depleted cells (KO) relative to WT mESC (y-axis). Transcript expression was first normalized by the amount of *Act- β* and *PolIII* and next by the total amount of transfected vectors per cell estimated based on the levels of relative *Neomycin* expression. Each point corresponds to the results of one independent biological replicate. Statistics: *-p<0.05, **-p<0.01 and ***-p<0.001 two-tailed paired t-test.

References

1. Bartel DP: **MicroRNAs: genomics, biogenesis, mechanism, and function.** *Cell* 2004, **116**:281-297.
2. Bartel DP: **MicroRNAs: target recognition and regulatory functions.** *Cell* 2009, **136**:215-233.
3. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Radmark O, Kim S, Kim VN: **The nuclear RNase III Drosha initiates microRNA processing.** *Nature* 2003, **425**:415-419.
4. Hutvagner G, McLachlan J, Pasquinelli AE, Balint E, Tuschl T, Zamore PD: **A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA.** *Science* 2001, **293**:834-838.
5. Kim YK, Kim B, Kim VN: **Re-evaluation of the roles of DROSHA, Exportin 5, and DICER in microRNA biogenesis.** *Proc Natl Acad Sci U S A* 2016, **113**:E1881-1889.
6. Bartel DP: **Metazoan MicroRNAs.** *Cell* 2018, **173**:20-51.
7. Jonas S, Izaurralde E: **Towards a molecular understanding of microRNA-mediated gene silencing.** *Nat Rev Genet* 2015, **16**:421-433.
8. Iwakawa HO, Tomari Y: **The Functions of MicroRNAs: mRNA Decay and Translational Repression.** *Trends Cell Biol* 2015, **25**:651-665.
9. Selbach M, Schwanhauser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N: **Widespread changes in protein synthesis induced by microRNAs.** *Nature* 2008, **455**:58-63.
10. Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP: **The impact of microRNAs on protein output.** *Nature* 2008, **455**:64-71.
11. Bethune J, Artus-Revel CG, Filipowicz W: **Kinetic analysis reveals successive steps leading to miRNA-mediated silencing in mammalian cells.** *EMBO Rep* 2012, **13**:716-723.
12. Pitchiaya S, Androsavich JR, Walter NG: **Intracellular single molecule microscopy reveals two kinetically distinct pathways for microRNA assembly.** *EMBO Rep* 2012, **13**:709-715.
13. Olsen PH, Ambros V: **The lin-4 regulatory RNA controls developmental timing in *Caenorhabditis elegans* by blocking LIN-14 protein synthesis after the initiation of translation.** *Dev Biol* 1999, **216**:671-680.
14. Tat TT, Maroney PA, Chamnongpol S, Collier J, Nilsen TW: **Cotranslational microRNA mediated messenger RNA destabilization.** *Elife* 2016, **5**.
15. Gu S, Jin L, Zhang F, Sarnow P, Kay MA: **Biological basis for restriction of microRNA targets to the 3' untranslated region in mammalian mRNAs.** *Nat Struct Mol Biol* 2009, **16**:144-150.
16. Seggerson K, Tang L, Moss EG: **Two genetic circuits repress the *Caenorhabditis elegans* heterochronic gene lin-28 after translation initiation.** *Dev Biol* 2002, **243**:215-225.
17. Wightman B, Ha I, Ruvkun G: **Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in *C. elegans*.** *Cell* 1993, **75**:855-862.
18. Nottrott S, Simard MJ, Richter JD: **Human let-7a miRNA blocks protein production on actively translating polyribosomes.** *Nat Struct Mol Biol* 2006, **13**:1108-1114.

- 1 19. Petersen CP, Bordeleau ME, Pelletier J, Sharp PA: **Short RNAs repress translation**
2 **after initiation in mammalian cells.** *Mol Cell* 2006, **21**:533-542.
- 3 20. Maroney PA, Yu Y, Fisher J, Nilsen TW: **Evidence that microRNAs are associated with**
4 **translating messenger RNAs in human cells.** *Nat Struct Mol Biol* 2006, **13**:1102-
5 1107.
- 6 21. Nelson PT, Hatzigeorgiou AG, Mourelatos Z: **miRNP:mRNA association in**
7 **polyribosomes in a human neuronal cell line.** *RNA* 2004, **10**:387-394.
- 8 22. Kim J, Krichevsky A, Grad Y, Hayes GD, Kosik KS, Church GM, Ruvkun G: **Identification**
9 **of many microRNAs that copurify with polyribosomes in mammalian neurons.** *Proc*
10 *Natl Acad Sci U S A* 2004, **101**:360-365.
- 11 23. Fabian MR, Mathonnet G, Sundermeier T, Mathys H, Zipprich JT, Svitkin YV, Rivas F,
12 Jinek M, Wohlschlegel J, Doudna JA, et al: **Mammalian miRNA RISC recruits CAF1**
13 **and PABP to affect PABP-dependent deadenylation.** *Mol Cell* 2009, **35**:868-880.
- 14 24. Wakiyama M, Takimoto K, Ohara O, Yokoyama S: **Let-7 microRNA-mediated mRNA**
15 **deadenylation and translational repression in a mammalian cell-free system.** *Genes*
16 *Dev* 2007, **21**:1857-1862.
- 17 25. Eulalio A, Huntzinger E, Nishihara T, Rehwinkel J, Fauser M, Izaurralde E:
18 **Deadenylation is a widespread effect of miRNA regulation.** *RNA* 2009, **15**:21-32.
- 19 26. Guttman M, Russell P, Ingolia NT, Weissman JS, Lander ES: **Ribosome profiling**
20 **provides evidence that large noncoding RNAs do not encode proteins.** *Cell* 2013,
21 **154**:240-251.
- 22 27. Helwak A, Kudla G, Dudnakova T, Tollervey D: **Mapping the human miRNA**
23 **interactome by CLASH reveals frequent noncanonical binding.** *Cell* 2013, **153**:654-
24 665.
- 25 28. Tan JY, Sirey T, Honti F, Graham B, Piovesan A, Merckenschlager M, Webber C,
26 Ponting CP, Marques AC: **Extensive microRNA-mediated crosstalk between lncRNAs**
27 **and mRNAs in mouse embryonic stem cells.** *Genome Res* 2015, **25**:655-666.
- 28 29. Ingolia NT, Lareau LF, Weissman JS: **Ribosome profiling of mouse embryonic stem**
29 **cells reveals the complexity and dynamics of mammalian proteomes.** *Cell* 2011,
30 **147**:789-802.
- 31 30. Leung AK, Young AG, Bhutkar A, Zheng GX, Bosson AD, Nielsen CB, Sharp PA:
32 **Genome-wide identification of Ago2 binding sites from mouse embryonic stem**
33 **cells with and without mature microRNAs.** *Nat Struct Mol Biol* 2011, **18**:237-244.
- 34 31. Cobb BS, Nesterova TB, Thompson E, Hertweck A, O'Connor E, Godwin J, Wilson CB,
35 Brockdorff N, Fisher AG, Smale ST, Merckenschlager M: **T cell lineage choice and**
36 **differentiation in the absence of the RNase III enzyme Dicer.** *J Exp Med* 2005,
37 **201**:1367-1373.
- 38 32. Nesterova TB, Popova BC, Cobb BS, Norton S, Senner CE, Tang YA, Spruce T,
39 Rodriguez TA, Sado T, Merckenschlager M, Brockdorff N: **Dicer regulates Xist**
40 **promoter methylation in ES cells indirectly through transcriptional control of**
41 **Dnmt3a.** *Epigenetics Chromatin* 2008, **1**:2.
- 42 33. Zheng GX, Do BT, Webster DE, Khavari PA, Chang HY: **Dicer-microRNA-Myc circuit**
43 **promotes transcription of hundreds of long noncoding RNAs.** *Nat Struct Mol Biol*
44 2014, **21**:585-590.
- 45 34. Judson RL, Babiarz JE, Venere M, Blelloch R: **Embryonic stem cell-specific microRNAs**
46 **promote induced pluripotency.** *Nat Biotechnol* 2009, **27**:459-461.

- 1 35. Wang Y, Baskerville S, Shenoy A, Babiarz JE, Baehner L, Blelloch R: **Embryonic stem**
2 **cell-specific microRNAs regulate the G1-S transition and promote rapid**
3 **proliferation.** *Nat Genet* 2008, **40**:1478-1483.
- 4 36. de Pretis S, Kress T, Morelli MJ, Melloni GE, Riva L, Amati B, Pelizzola M: **INSPECT: a**
5 **computational tool to infer mRNA synthesis, processing and degradation dynamics**
6 **from RNA- and 4sU-seq time course experiments.** *Bioinformatics* 2015, **31**:2829-
7 2835.
- 8 37. Braun KA, Young ET: **Coupling mRNA synthesis and decay.** *Mol Cell Biol* 2014,
9 **34**:4078-4087.
- 10 38. Haimovich G, Medina DA, Causse SZ, Garber M, Millan-Zambrano G, Barkai O, Chavez
11 S, Perez-Ortin JE, Darzacq X, Choder M: **Gene expression is circular: factors for**
12 **mRNA degradation also foster mRNA synthesis.** *Cell* 2013, **153**:1000-1011.
- 13 39. Dahan O, Gingold H, Pilpel Y: **Regulatory mechanisms and networks couple the**
14 **different phases of gene expression.** *Trends Genet* 2011, **27**:316-322.
- 15 40. Makarewich CA, Olson EN: **Mining for Micropeptides.** *Trends Cell Biol* 2017, **27**:685-
16 696.
- 17 41. Lin MF, Jungreis I, Kellis M: **PhyloCSF: a comparative genomics method to**
18 **distinguish protein coding and non-coding regions.** *Bioinformatics* 2011, **27**:i275-
19 282.
- 20 42. Pitchiaya S, Mourao MDA, Jalihal AP, Xiao L, Jiang X, Chinnaiyan AM, Schnell S,
21 Walter NG: **Dynamic Recruitment of Single RNAs to Processing Bodies Depends on**
22 **RNA Functionality.** *Mol Cell* 2019, **74**:521-533 e526.
- 23 43. Eulalio A, Behm-Ansmant I, Izaurralde E: **P bodies: at the crossroads of post-**
24 **transcriptional pathways.** *Nat Rev Mol Cell Biol* 2007, **8**:9-22.
- 25 44. Chen Y, Boland A, Kuzuoglu-Ozturk D, Bawankar P, Loh B, Chang CT, Weichenrieder
26 O, Izaurralde E: **A DDX6-CNOT1 complex and W-binding pockets in CNOT9 reveal**
27 **direct links between miRNA target recognition and silencing.** *Mol Cell* 2014, **54**:737-
28 750.
- 29 45. Chu CY, Rana TM: **Translation repression in human cells by microRNA-induced gene**
30 **silencing requires RCK/p54.** *PLoS Biol* 2006, **4**:e210.
- 31 46. Rouya C, Siddiqui N, Morita M, Duchaine TF, Fabian MR, Sonenberg N: **Human DDX6**
32 **effects miRNA-mediated gene silencing via direct binding to CNOT1.** *RNA* 2014,
33 **20**:1398-1409.
- 34 47. Freimer JW, Hu TJ, Blelloch R: **Decoupling the impact of microRNAs on translational**
35 **repression versus RNA degradation in embryonic stem cells.** *Elife* 2018, **7**.
- 36 48. Wang Y, Xu Z, Jiang J, Xu C, Kang J, Xiao L, Wu M, Xiong J, Guo X, Liu H: **Endogenous**
37 **miRNA sponge lincRNA-RoR regulates Oct4, Nanog, and Sox2 in human embryonic**
38 **stem cell self-renewal.** *Dev Cell* 2013, **25**:69-80.
- 39 49. Cesana M, Cacchiarelli D, Legnini I, Santini T, Sthandier O, Chinappi M, Tramontano
40 A, Bozzoni I: **A long noncoding RNA controls muscle differentiation by functioning**
41 **as a competing endogenous RNA.** *Cell* 2011, **147**:358-369.
- 42 50. Tan JY, Vance KW, Varela MA, Sirey T, Watson LM, Curtis HJ, Marinello M, Alves S,
43 Steinkraus B, Cooper S, et al: **Cross-talking noncoding RNAs contribute to cell-**
44 **specific neurodegeneration in SCA7.** *Nat Struct Mol Biol* 2014, **21**:955-961.
- 45 51. Denzler R, Agarwal V, Stefano J, Bartel DP, Stoffel M: **Assessing the ceRNA**
46 **hypothesis with quantitative measurements of miRNA and target abundance.** *Mol*
47 *Cell* 2014, **54**:766-776.

- 1 52. Bosson AD, Zamudio JR, Sharp PA: **Endogenous miRNA and target concentrations**
2 **determine susceptibility to potential ceRNA competition.** *Mol Cell* 2014, **56**:347-
3 359.
- 4 53. Hausser J, Zavolan M: **Identification and consequences of miRNA-target**
5 **interactions--beyond repression of gene expression.** *Nat Rev Genet* 2014, **15**:599-
6 612.
- 7 54. Graham B, Marcais A, Dharmalingam G, Carroll T, Kanellopoulou C, Graumann J,
8 Nesterova TB, Bermange A, Brazauskas P, Xella B, et al: **MicroRNAs of the miR-290-**
9 **295 Family Maintain Bivalency in Mouse Embryonic Stem Cells.** *Stem Cell Reports*
10 2016, **6**:635-642.
- 11 55. Kozomara A, Birgaoanu M, Griffiths-Jones S: **miRBase: from microRNA sequences to**
12 **function.** *Nucleic Acids Res* 2019, **47**:D155-D162.
- 13 56. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M,
14 Gingeras TR: **STAR: ultrafast universal RNA-seq aligner.** *Bioinformatics* 2013, **29**:15-
15 21.
- 16 57. Li B, Dewey CN: **RSEM: accurate transcript quantification from RNA-Seq data with**
17 **or without a reference genome.** *BMC Bioinformatics* 2011, **12**:323.
- 18 58. M M: **Cutadapt removes adapter sequences from high-throughput sequencing**
19 **reads.** *EMBnet J* 2011, **17**:10-12.
- 20 59. Langmead B, Trapnell C, Pop M, Salzberg SL: **Ultrafast and memory-efficient**
21 **alignment of short DNA sequences to the human genome.** *Genome Biol* 2009,
22 **10**:R25.
- 23 60. Corcoran DL, Georgiev S, Mukherjee N, Gottwein E, Skalsky RL, Keene JD, Ohler U:
24 **PARalyzer: definition of RNA binding sites from PAR-CLIP short-read sequence**
25 **data.** *Genome Biol* 2011, **12**:R79.
- 26 61. Quinlan AR, Hall IM: **BEDTools: a flexible suite of utilities for comparing genomic**
27 **features.** *Bioinformatics* 2010, **26**:841-842.
- 28 62. Cunningham F, Achuthan P, Akanni W, Allen J, Amode MR, Armean IM, Bennett R,
29 Bhai J, Billis K, Boddu S, et al: **Ensembl 2019.** *Nucleic Acids Res* 2019, **47**:D745-D751.
- 30 63. Langmead B, Salzberg SL: **Fast gapped-read alignment with Bowtie 2.** *Nat Methods*
31 2012, **9**:357-359.
- 32 64. Robinson MD, McCarthy DJ, Smyth GK: **edgeR: a Bioconductor package for**
33 **differential expression analysis of digital gene expression data.** *Bioinformatics*
34 2010, **26**:139-140.
- 35 65. Sarker KP, Wilson SM, Bonni S: **SnoN is a cell type-specific mediator of transforming**
36 **growth factor-beta responses.** *Journal of Biological Chemistry* 2005, **280**:13037-
37 13046.
- 38
39

1 **Supplementary Figure and Table Legends**

2

3 **Supplementary Table S1- Gene IDs and locations of putative micropeptides.**

4

5 **Supplementary Table S2- Location and identity of lncRNA-c1 predicted miRNA**
6 **recognition sites for mESC expressed miRNAs.** Only miRNAs belonging to the 14
7 families that account for 75% of all miRNA counts, as estimated using nanostring in
8 [28], were considered. MREs mutated in GFP-lncRNA-c1 Δ MRE are highlighted in
9 red.

10

11 **Supplementary Table S3- Primer table.**

12

13 **Supplementary Figure S1-** (A) Distribution of log₁₀ ratio between nuclear/cytosolic
14 (transcripts per million, tpm) in mESCs for mRNAs (red) and lncRNAs (blue) (B)
15 Distribution of the expression (tpm) of transcripts with and without experimental
16 evidence for AGO2 binding in mESCs. (C) Immunoblot analysis of DICER (DCR) in
17 protein extracts from DICER conditional mESCs 8 days after treatment with ethanol
18 (WT) or tamoxifen (KO) for three independent biological replicates (BR1-3). ACTIN-
19 β (ACT) was used as an internal control and to quantify the relative difference in
20 DICER levels represented in bar plot. (D) Percentage of proliferating cells after 8 days
21 of treatment with ethanol (WT) or 4-OHT (KO) for 3 independent treatments. (E) Fold
22 -change in *Oct4* (two-tailed t-test p-value=0.48), *Nanog* (two-tailed t-test p-
23 value=0.09), *Myc* (two-tailed t-test p-value=0.036), *Sox2* (two-tailed t-test p-
24 value=0.38) and *Dicer* (x-axis) (two-tailed t-test p-value<0.0001) expression KO
25 relative to WT cells measured for 3 independent biological replicates (y-axis). Western
26 blot using antibodies against mouse OCT4 (two-tailed t-test p-value=0.88) (F) and
27 NANOG (two-tailed t-test p-value=0.70) (G) in protein extracts from DICER conditional
28 mESCs 8 days after treatment with ethanol (WT) or 4-OHT (KO) for three independent
29 biological replicates (BR1-3). ACTIN- β (ACT) was used as an internal control and to
30 determine the relative difference in DICER levels represented in bar plot. (H)
31 Expression of miR-295 and miR-290 relative to sno-202 (x-axis) in Dcr conditional
32 mESCs 8 days after treatment with ethanol (WT) or tamoxifen (KO) (y-axis) for three
33 independent biological replicates. (I) Fold -change in *Cdkn1a*, *Lats2* and *Rbl2* (x-axis)
34 expression KO relative to WT cells measured for 3 independent biological replicates
35 (y-axis). Uncropped blots used to assemble panels C, F and G are provided in
36 Supplementary Files 1-2.

37

38 **Supplementary Figure S2-** Principal component analysis of gene expression. The
39 first 2 axis (PCA1 and PCA2) separate samples into (A) RNA fraction, nascent RNA
40 (NS, red) and preexisting RNA (PE blue) and (B) cell type, DICER knockout (KO, red)
41 and wild-type (WT, blue). (C) PCA2 and PCA3 separate biological replicates (BR1 red
42 and BR2 blue). (D) Fold-change in 4sU degradation rate between KO and WT cells (X
43 axis) is inversely correlated with the fold-change in relative expression between KO
44 and WT after 8 hours of treatment with Actinomycin-D (y-axis). Points represent the
45 mean and standard deviation based on 3 independent biological replicates. (E)
46 Volcano plot showing the adjusted p-value (y-axis) as a function of the fold-change in
47 degradation rate, estimates based on the 15 minutes pulse, between KO and WT cells
48 (x-axis) for protein-coding genes (red), cytosolic (blue) and nuclear (grey) lncRNAs.
49 Each point represents a transcript and horizontal dashed line the significance cut-off.
50 (F) Cumulative distribution plot of the density of AGO2 clusters in the 3'unstrated

1 regions of mRNAs bound (AGO2 cluster>0) whose degradation rates were either
2 significantly (red) or not significantly changed (black) between KO and WT cells, based
3 on the 15 minutes pulse estimates. (G) Distribution of the fold-change after 8 days of
4 tamoxifen treatment in degradation rate (estimated based on the 15 minutes pulse) of
5 mRNAs (red), cytosolic (blue) and nuclear (grey) lncRNAs, in KO relative to WT cells.
6 (H) Distribution of the fold-change after 8 days of tamoxifen treatment in synthesis rate
7 of mRNAs (red), cytosolic (blue) and nuclear (grey) lncRNAs, in KO relative to WT
8 cells. Results for the 10- and 15-minutes pulse are presented separately.

9
10 **Supplementary Figure S3-** (A) Genome browser view of the region encompassing
11 *lncRNA-c1* (black, chr2: 156388130-156391779). Gencode annotated genes are
12 annotated in blue. (B) Distribution of gene expression (log10tpm, x-axis) for all mESC
13 expressed transcripts. Red dotted horizontal line indicates the expression of *lncRNA-*
14 *c1*. (C) Expression of *lncRNA-c1* (TPM), measured by RNA sequencing, 8 days after
15 induction of DICER loss of function in wild-type (WT, circles) and 4-OHT treated (KO,
16 triangles) mESCs. Each point represents the expression measured in one of the
17 biological replicates. (D) Fold-change in *lncRNA-c1*, *Lats2* and *Cdkn1a* expression
18 relative to WT cells, measured by qPCR in WT (circles) and 4-OHT treated (KO,
19 triangles) mESCs. Transcript expression was normalized by the amount of *Act-β* and
20 *PolIII*. (E) Fold-change in stability, measured as the relative amount of transcript
21 detected after 8 hours of transcription block using Actinomycin-D, for *lncRNA-c1*,
22 *Lats2* and *Cdkn1a* expression relative to WT cells. Expression was measured by
23 qPCR after in WT (circles) and 4-OHT treated (KO, triangles) mESCs for three
24 independent experiments. (F) Log10 of the fold change in expression in the nuclear
25 and cytosolic fraction. Measured by qPCR, for *lncRNA-c1* and a nuclear (*Malat1*) and
26 cytosolic (*Gapdh*) control. (G) Representative western blot analysis of protein extracts
27 from input, AGO2-RIP and IgG control. AGO2 was probed with rabbit AGO2 antibody
28 (top panel). After membrane stripping and re-probing with mouse anti-AGO2 (middle
29 panel) unspecific band in IgG was cleared. Probing with rabbit antibody confirmed the
30 presence of DICER specifically in the input and AGO2-RIP samples (lower panel). (H)
31 qPCR quantification of *lncRNA-c1* and *Cdkn1a* (x-axis) bound in AGO2-IP (triangles)
32 relative to input and unspecific IgG (circles) antibody relative to input (y-axis).

33
34 **Supplementary Figure S4-** (A) Pairwise alignment of the constructs sequencing
35 results for *Cdkn1a* (top) and *Cdkn1aΔATG* (bottom). *Cdkn1a* start codon is highlighted
36 in red. Predicted peptides encode by (B) *Cdkn1a* and (C) *Cdkn1aΔATG* (same frame).
37 (D) Fold-change in stability, measured as the relative amount of transcript, normalized
38 to *Act-β*, detected after 8 hours of transcription block using Actinomycin-D, for *GFP*,
39 *GFP-lncRNA-c1* and *lncRNA-c1* (x-axis) in miRNA depleted cells relative to WT cells
40 (y-axis). (D) Pairwise alignment between miR-295 (top) and miR-290 (bottom) and
41 respective predicted miRNA response elements (MRE) within *lncRNA-c1*. MRE start
42 position within annotated *lncRNA-c1* transcript (TCONS_00034281) is indicated inside
43 parenthesis. (E) Fold change in expression, of *GFP*, *GFP-lncRNA-c1* and *GFP-*
44 *lncRNA-c1-MREΔ* (x-axis) in miRNA depleted cells transfected with negative control
45 (NC) relative to miRNA depleted cells transfected with miRNA mimics (miRNA) (y-
46 axis). Transcript expression was first normalized by the amount of *Act-β* and *PolIII* and
47 next by the total amount of transfected vectors per cell estimated based on the levels
48 of relative *Neomycin* expression. Each point corresponds to the results of one
49 independent biological replicate. Lines connecting data-points represent pairing of the
50 three independent replicates. (F) Relative expression of *GFP-lncRNA-c1* and *GFP-*

1 *lncRNA-c1-MREΔ* (x-axis) in wild-type mESC (WT). Transcript expression was first
2 normalized by the amount of *Act-β* and *PoIII* and next by the total amount of
3 transfected vectors per cell estimated based on the levels of relative *Neomycin*
4 expression. Each point corresponds to the results of one independent biological
5 replicate. Statistics: *-p<0.05, **-p<0.01 and ***-p<0.001 two-tailed paired t-test.

6
7
8

Figure 1- Steady state abundance of lncRNAs are not directly affected by loss of miRNAs.




Figure 2- No evidence for miRNA-dependent stabilisation of cytosolic mRNAs.




Figure 3-Micropeptide encoding transcript expression is posttranscriptionally regulated by miRNAs.




Figure 4- Association of lincRNA-c1 with translating ribosomes results in its miRNA-dependent decay




Figure S1




Figure S2




Figure S3




Figure S4

